Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis

被引:1
作者
Zou, Shu-Peng [1 ]
Cheng, Qian [1 ]
Feng, Cheng-Yang [1 ]
Xu, Chan [1 ]
Sun, Ming-Hui [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430000, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, 1095 Jiefang Ave, Wuhan 430000, Hubei, Peoples R China
关键词
Helicobacter pylori; Clarithromycin resistance; First-line therapy; Proton pump inhibitors; RANDOMIZED CONTROLLED-TRIAL; STANDARD TRIPLE THERAPY; SEQUENTIAL THERAPY; QUADRUPLE THERAPY; 7-DAY CONCOMITANT; OPEN-LABEL; VONOPRAZAN; MULTICENTER; EFFICACY; CLARITHROMYCIN;
D O I
10.12998/wjcc.v10.i35.12959
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND As a first-line treatment regimen for Helicobacter pylori (H. pylori) infection, antibiotic therapy is widely used worldwide. However, the question of increasing antibiotic resistance must be considered. Given this issue, we need to find ways to reduce drug resistance. This study examined all currently available first-line regimens and compared them with standard triple treatment through a network meta-analysis of randomized controlled trials (RCTs). AIM To compare first-line treatment regimens for eradication of antibiotic-resistant H. pylori strains. METHODS To compare the effectiveness of the first-line regimens for treating H. pylori infection, a Bayesian network meta-analysis was applied to process data extracted from RCTs. The plausible ranking for each regimen was assessed by the surface under the cumulative ranking curve (SUCRA). In addition, we conducted a relevant search by reference citation analysis. RESULTS Twenty-five RCTs involving 12029 participants [including 1602 infected with clarithromycin (CAM)-resistant strains and 1716 infected with metronidazole (MNZ)-resistant strains] were included, in which a total of seven regimens were used for H. pylori eradication. The results showed that dual therapy containing a high-dose proton pump inhibitor (HDDT) [odds ratio (OR): 4.20, 95% confidence interval (CI): 2.29-8.13] was superior to other therapies for all patients, including those with CAM/MNZ-resistant H. pylori infection. In the comparative effectiveness ranking, for CAM-resistant H. pylori, HDDT (OR: 96.80, 95%CI: 22.46-521.9) had the best results, whereas standard triple therapy ranked last (SUCRA: 98.7% vs 0.3%). In the subgroup of high cure rates (>= 90%), HDDT was also generally better than other therapies. CONCLUSION For the eradication of CAM- and MNZ-resistant H. pylori strains, HDDT exhibited considerable advantages. The studies of CAM-resistant H. pylori were based on small samples due to a lack of antibiotic sensitivity tests in many RCTs, but the results showed that all patients, including those with CAM-resistant H. pylori infection, had a concordant trend. Overall, HDDT may be a reference for RCTs and other studies of H. pylori eradication.
引用
收藏
页码:12959 / 12970
页数:12
相关论文
共 48 条
[1]   Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study [J].
Ban, Hiromitsu ;
Inatomi, Osamu ;
Murata, Masaki ;
Otsuka, Taketo ;
Oi, Masayuki ;
Matsumoto, Hiroshi ;
Bamba, Shigeki ;
Andoh, Akira .
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2021, 68 (03) :259-263
[2]   Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: a prospective randomized trial [J].
Chen, Kuan-Yang ;
Lin, Tsung-Jung ;
Lin, Chin-Lin ;
Lee, Hsi-Chang ;
Wang, Chung-Kwe ;
Wu, Deng-Chyang .
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (36) :10435-10442
[3]   Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial [J].
Chey, William D. ;
Megraud, Francis ;
Laine, Loren ;
Lopez, Luis J. ;
Hunt, Barbara J. ;
Howden, Colin W. .
GASTROENTEROLOGY, 2022, 163 (03) :608-619
[4]   Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection [J].
Furuta, Takahisa ;
Graham, David Y. .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2010, 39 (03) :465-+
[5]   An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection [J].
Georgopoulos, Sotirios ;
Papastergiou, Vasilios .
EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) :729-741
[6]   Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy [J].
Graham, David Y. ;
Hernaez, Ruben ;
Rokkas, Theodore .
GUT, 2022, 71 (03) :643-650
[7]   Vonoprazan-containingHelicobacter pyloritriple therapies contribution to global antimicrobial resistance [J].
Graham, David Y. ;
Lu, Hong ;
Shiotani, Akiko .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (05) :1159-1163
[8]   Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial [J].
Guan, Jia-Lun ;
Hu, Yun-Lian ;
An, Ping ;
He, Qiong ;
Long, Hui ;
Zhou, Lin ;
Chen, Zhi-Fen ;
Xiong, Jian-Guang ;
Wu, Shi-Sheng ;
Ding, Xiang-Wu ;
Luo, He-Sheng ;
Li, Pei-Yuan .
PHARMACOTHERAPY, 2022, 42 (03) :224-232
[9]   Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study [J].
Gunaratne, Anoja W. ;
Hamblin, Harrison ;
Clancy, Annabel ;
Magat, Aleja Jane Marie C. ;
Dawson, Marie Vic M. ;
Tu, Jeffrey ;
Borody, Thomas J. .
HELICOBACTER, 2021, 26 (05)
[10]   Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial [J].
Hsu, Ping-, I ;
Tsay, Feng-Woei ;
Graham, David Y. ;
Tsai, Tzung-Jiun ;
Tsai, Kuo-Wang ;
Kao, John Y. ;
Peng, Nan-Jing ;
Kuo, Chao-Hung ;
Kao, Sung-Shuo ;
Wang, Huay-Min ;
Lin, Te-Fu ;
Wu, Deng-Chyang .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (09) :1427-1433